1.86
price up icon14.11%   0.23
pre-market  Pre-mercato:  1.93   0.07   +3.76%
loading
Precedente Chiudi:
$1.63
Aprire:
$1.65
Volume 24 ore:
94,408
Relative Volume:
1.70
Capitalizzazione di mercato:
$13.60M
Reddito:
$10.16M
Utile/perdita netta:
$-47.57M
Rapporto P/E:
-0.2257
EPS:
-8.24
Flusso di cassa netto:
$-42.73M
1 W Prestazione:
+43.08%
1M Prestazione:
-19.83%
6M Prestazione:
-62.20%
1 anno Prestazione:
-87.15%
Intervallo 1D:
Value
$1.65
$1.89
Intervallo di 1 settimana:
Value
$1.30
$1.89
Portata 52W:
Value
$1.02
$16.99

Curis Inc Stock (CRIS) Company Profile

Name
Nome
Curis Inc
Name
Telefono
617-503-6500
Name
Indirizzo
128 SPRING STREET, LEXINGTON, MA
Name
Dipendente
33
Name
Cinguettio
@curisinc
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
CRIS's Discussions on Twitter

Confronta CRIS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRIS
Curis Inc
1.86 13.60M 10.16M -47.57M -42.73M -8.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Curis Inc Stock (CRIS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-11-17 Iniziato Truist Buy
2022-04-04 Downgrade Raymond James Outperform → Mkt Perform
2021-10-13 Iniziato Raymond James Outperform
2021-03-25 Iniziato B. Riley Securities Buy
2020-07-29 Iniziato Laidlaw Buy
2020-07-17 Iniziato Cantor Fitzgerald Overweight
2017-10-24 Iniziato Guggenheim Buy
2016-03-02 Iniziato Sun Trust Rbsn Humphrey Buy
2015-11-09 Reiterato ROTH Capital Buy
2015-08-11 Iniziato FBR Capital Outperform
2015-01-22 Reiterato Oppenheimer Outperform
2015-01-21 Reiterato ROTH Capital Buy
2014-05-09 Reiterato Oppenheimer Outperform
2013-10-02 Iniziato Robert W. Baird Outperform
2013-09-30 Iniziato Chardan Capital Markets Buy
2012-11-14 Iniziato Stifel Nicolaus Hold
2012-01-31 Reiterato Brean Murray Buy
2012-01-31 Reiterato Summer Street Research Buy
2011-12-09 Iniziato Oppenheimer Outperform
2011-10-06 Iniziato Summer Street Research Buy
2011-09-22 Iniziato MLV Capital Buy
2011-03-21 Reiterato Brean Murray Buy
2010-02-26 Reiterato Roth Capital Buy
2010-01-07 Iniziato Roth Capital Buy
Mostra tutto

Curis Inc Borsa (CRIS) Ultime notizie

pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 22, 2025

Curis (NASDAQ:CRIS) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 22, 2025
pulisher
Apr 14, 2025

Curis (NASDAQ:CRIS) Now Covered by StockNews.com - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Curis, Inc. and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration - marketscreener.com

Apr 13, 2025
pulisher
Apr 10, 2025

Form DEFA14A CURIS INC - StreetInsider

Apr 10, 2025
pulisher
Apr 10, 2025

Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call Transcript - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

Curis stock plunges to 52-week low at $1.1 amid sharp decline - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Curis stock plunges to 52-week low at $1.1 amid sharp decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Truist Removes Price Target on Curis Due to Volatility, Low Share Price; Price Target Was $26, Buy Rating Kept - marketscreener.com

Apr 09, 2025
pulisher
Apr 04, 2025

Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Forecasts Curis’ Q1 Earnings (NASDAQ:CRIS) - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher - Yahoo

Apr 03, 2025
pulisher
Apr 03, 2025

Curis to Present at Upcoming Healthcare Conference in April - The Malaysian Reserve

Apr 03, 2025
pulisher
Apr 03, 2025

Curis to Present at Upcoming Healthcare Conference in April 2025 - BioSpace

Apr 03, 2025
pulisher
Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS) - simplywall.st

Apr 02, 2025
pulisher
Apr 02, 2025

HC Wainwright Lowers Curis (NASDAQ:CRIS) Price Target to $16.00 - The AM Reporter

Apr 02, 2025
pulisher
Apr 01, 2025

Curis stock price target cut to $16 by H.C. Wainwright - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Curis stock plunges to 52-week low at $1.97 amid market challenges - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates - Yahoo

Apr 01, 2025
pulisher
Apr 01, 2025

Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30% - simplywall.st

Apr 01, 2025
pulisher
Apr 01, 2025

Curis: Q4 Earnings Snapshot - CT Insider

Apr 01, 2025
pulisher
Apr 01, 2025

Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Curis (NASDAQ:CRIS) Price Target Lowered to $16.00 at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Curis Inc. Reports Q4 2024 Progress and Financials - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Curis Inc. Earnings Call: Progress Amidst Challenges - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Curis eyes accelerated approval for cancer drug emavusertib By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Curis Q4 2024 reveals reduced losses By Investing.com - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Curis eyes accelerated approval for cancer drug emavusertib - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Curis Provides Fourth Quarter 2024 Business Update - PR Newswire

Mar 31, 2025
pulisher
Mar 30, 2025

Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance

Mar 30, 2025
pulisher
Mar 29, 2025

Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Quantisnow

Mar 28, 2025
pulisher
Mar 28, 2025

Curis Inc Entered A Purchase Agreement To Sell 2 Million Shares Of Common Stock - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Mar 28, 2025
pulisher
Mar 28, 2025

Biotech Alert: Curis Sets Date for Q4 EarningsKey Updates on IRAK4 Inhibitor Program Expected - Stock Titan

Mar 28, 2025
pulisher
Mar 25, 2025

Curis stock hits 52-week low at $2.54 amid sharp annual decline - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Curis stock hits 52-week low at $2.54 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 24, 2025

Curis Inc Azioni (CRIS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Capitalizzazione:     |  Volume (24 ore):